Skip to main content

Table 1 Patients‘data

From: Short term cognitive function after sevoflurane anesthesia in patients suspect to obstructive sleep apnea syndrome: an observational study

 

Low risk (n = 23)

Moderate to high risk (n = 23)

P value

Demographics

 Age (yrs.)

67.8 (60–84)

68.4 (60.7–76.8)

0.885

 Sex (female/male)

12/11

5/18

0.065

 Body mass index (BMI) (kg m−2)

25.7 (19.4–32.6)

29.4 (23.4–38.1)

0.002*

 ASA classification (I/II/III)

4/18/1

0/18/5

0.022*

 STOP-BANG score

2 (1–2)

4 (3–6)

< 0.001*

Comorbidities

 History of smoking (no/yes/past)

16/6/1

14/2/7

0.041*

 Arterial hypertension

6

15

0.017*

 Diabetes mellitus (DM)

1

5

0.187

Surgery

 Otorhinolaryngologic surgery

19

21

n.s.

 Other type of Surgery

4

2

n.s.

Surgery type details

 Skin surgery

2

1

1.000

 Thyroid gland surgery

2

0

0.489

 Ear surgery

8

5

0.514

 Nasal and paranasal sinus surgery

4

10

0.108

 Salivary gland surgery

7

6

1.000

 Midfacial fracture surgery

0

1

1.000

Operation data

 Duration of anaesthesia (h)

1.9 (1.1–4.2)

1.8 (1.1–4.3)

0.667

 Extubation to 2nd testing time (h)

27.0 (5.9–50.1)

26.4 (19.4–47.5)

0.657

 SpO2 before procedure (%)

97 (91–100)

97 (89–100)

0.729

 SpO2 at before transfer to intermediate care (%)

99 (87–100)

98 (92–100)

0.819

 SpO2 at arrival intermediate care (%)

95 (86–100)

92 (88–96)

0.073

 SpO2 lowest level (%)

93 (85–98)

91 (81–96)

0.141

Postoperative testing day

 First postoperative day

1

22

n.s.

 Second postoperative day

0

23

n.s.

  1. Data are reported as number or as median (range). SpO2 is the oxygen saturation measured by pulse oximetry. P value is the significance level of the difference between the two groups. (n.s. not significant)